Abstract
Summary
According to our LPI (LP Information) latest study, the global Neurodegenerative Disease Treatment market size was valued at US$ million in 2023. With growing demand in downstream market, the Neurodegenerative Disease Treatment is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Neurodegenerative Disease Treatment market. Neurodegenerative Disease Treatment are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Neurodegenerative Disease Treatment. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Neurodegenerative Disease Treatment market.
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Neurodegenerative Disease Treatment market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Neurodegenerative Disease Treatment market. It may include historical data, market segmentation by Type (e.g., Neurotransmitter Agents, Neuroprotective Agents), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Neurodegenerative Disease Treatment market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Neurodegenerative Disease Treatment market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Neurodegenerative Disease Treatment industry. This include advancements in Neurodegenerative Disease Treatment technology, Neurodegenerative Disease Treatment new entrants, Neurodegenerative Disease Treatment new investment, and other innovations that are shaping the future of Neurodegenerative Disease Treatment.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Neurodegenerative Disease Treatment market. It includes factors influencing customer ' purchasing decisions, preferences for Neurodegenerative Disease Treatment product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Neurodegenerative Disease Treatment market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Neurodegenerative Disease Treatment market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Neurodegenerative Disease Treatment market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Neurodegenerative Disease Treatment industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Neurodegenerative Disease Treatment market.
Market Segmentation:
Neurodegenerative Disease Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Neurotransmitter Agents
Neuroprotective Agents
Biologics
Others
Segmentation by application
Multiple Sclerosis [MS]
Alzheimer’s Disease
Parkinson's Disease
Acute Migraine
Autism
Narcolepsy
Amyotrophic Lateral Sclerosis [ALS]
Attention Deficit Hyperactivity Disorder [ADHD]
Spinal Muscular Atrophy
Huntington's Disease
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan plc
Bayer AG
F. Hoffmann La-Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson
Merck KGaA
Novartis AG
Pfizer, Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
The research report highlights the growth potential of the global Neurodegenerative Disease Treatment market. Neurodegenerative Disease Treatment are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Neurodegenerative Disease Treatment. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Neurodegenerative Disease Treatment market.
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Neurodegenerative Disease Treatment market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Neurodegenerative Disease Treatment market. It may include historical data, market segmentation by Type (e.g., Neurotransmitter Agents, Neuroprotective Agents), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Neurodegenerative Disease Treatment market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Neurodegenerative Disease Treatment market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Neurodegenerative Disease Treatment industry. This include advancements in Neurodegenerative Disease Treatment technology, Neurodegenerative Disease Treatment new entrants, Neurodegenerative Disease Treatment new investment, and other innovations that are shaping the future of Neurodegenerative Disease Treatment.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Neurodegenerative Disease Treatment market. It includes factors influencing customer ' purchasing decisions, preferences for Neurodegenerative Disease Treatment product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Neurodegenerative Disease Treatment market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Neurodegenerative Disease Treatment market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Neurodegenerative Disease Treatment market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Neurodegenerative Disease Treatment industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Neurodegenerative Disease Treatment market.
Market Segmentation:
Neurodegenerative Disease Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Neurotransmitter Agents
Neuroprotective Agents
Biologics
Others
Segmentation by application
Multiple Sclerosis [MS]
Alzheimer’s Disease
Parkinson's Disease
Acute Migraine
Autism
Narcolepsy
Amyotrophic Lateral Sclerosis [ALS]
Attention Deficit Hyperactivity Disorder [ADHD]
Spinal Muscular Atrophy
Huntington's Disease
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan plc
Bayer AG
F. Hoffmann La-Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson
Merck KGaA
Novartis AG
Pfizer, Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neurodegenerative Disease Treatment Market Size 2019-2030
2.1.2 Neurodegenerative Disease Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Neurodegenerative Disease Treatment Segment by Type
2.2.1 Neurotransmitter Agents
2.2.2 Neuroprotective Agents
2.2.3 Biologics
2.2.4 Others
2.3 Neurodegenerative Disease Treatment Market Size by Type
2.3.1 Neurodegenerative Disease Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Neurodegenerative Disease Treatment Market Size Market Share by Type (2019-2024)
2.4 Neurodegenerative Disease Treatment Segment by Application
2.4.1 Multiple Sclerosis [MS]
2.4.2 Alzheimer’s Disease
2.4.3 Parkinson's Disease
2.4.4 Acute Migraine
2.4.5 Autism
2.4.6 Narcolepsy
2.4.7 Amyotrophic Lateral Sclerosis [ALS]
2.4.8 Attention Deficit Hyperactivity Disorder [ADHD]
2.4.9 Spinal Muscular Atrophy
2.4.10 Huntington's Disease
2.5 Neurodegenerative Disease Treatment Market Size by Application
2.5.1 Neurodegenerative Disease Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Neurodegenerative Disease Treatment Market Size Market Share by Application (2019-2024)
3 Neurodegenerative Disease Treatment Market Size by Player
3.1 Neurodegenerative Disease Treatment Market Size Market Share by Players
3.1.1 Global Neurodegenerative Disease Treatment Revenue by Players (2019-2024)
3.1.2 Global Neurodegenerative Disease Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Neurodegenerative Disease Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Neurodegenerative Disease Treatment by Regions
4.1 Neurodegenerative Disease Treatment Market Size by Regions (2019-2024)
4.2 Americas Neurodegenerative Disease Treatment Market Size Growth (2019-2024)
4.3 APAC Neurodegenerative Disease Treatment Market Size Growth (2019-2024)
4.4 Europe Neurodegenerative Disease Treatment Market Size Growth (2019-2024)
4.5 Middle East & Africa Neurodegenerative Disease Treatment Market Size Growth (2019-2024)
5 Americas
5.1 Americas Neurodegenerative Disease Treatment Market Size by Country (2019-2024)
5.2 Americas Neurodegenerative Disease Treatment Market Size by Type (2019-2024)
5.3 Americas Neurodegenerative Disease Treatment Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurodegenerative Disease Treatment Market Size by Region (2019-2024)
6.2 APAC Neurodegenerative Disease Treatment Market Size by Type (2019-2024)
6.3 APAC Neurodegenerative Disease Treatment Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Neurodegenerative Disease Treatment by Country (2019-2024)
7.2 Europe Neurodegenerative Disease Treatment Market Size by Type (2019-2024)
7.3 Europe Neurodegenerative Disease Treatment Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neurodegenerative Disease Treatment by Region (2019-2024)
8.2 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Type (2019-2024)
8.3 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Neurodegenerative Disease Treatment Market Forecast
10.1 Global Neurodegenerative Disease Treatment Forecast by Regions (2025-2030)
10.1.1 Global Neurodegenerative Disease Treatment Forecast by Regions (2025-2030)
10.1.2 Americas Neurodegenerative Disease Treatment Forecast
10.1.3 APAC Neurodegenerative Disease Treatment Forecast
10.1.4 Europe Neurodegenerative Disease Treatment Forecast
10.1.5 Middle East & Africa Neurodegenerative Disease Treatment Forecast
10.2 Americas Neurodegenerative Disease Treatment Forecast by Country (2025-2030)
10.2.1 United States Neurodegenerative Disease Treatment Market Forecast
10.2.2 Canada Neurodegenerative Disease Treatment Market Forecast
10.2.3 Mexico Neurodegenerative Disease Treatment Market Forecast
10.2.4 Brazil Neurodegenerative Disease Treatment Market Forecast
10.3 APAC Neurodegenerative Disease Treatment Forecast by Region (2025-2030)
10.3.1 China Neurodegenerative Disease Treatment Market Forecast
10.3.2 Japan Neurodegenerative Disease Treatment Market Forecast
10.3.3 Korea Neurodegenerative Disease Treatment Market Forecast
10.3.4 Southeast Asia Neurodegenerative Disease Treatment Market Forecast
10.3.5 India Neurodegenerative Disease Treatment Market Forecast
10.3.6 Australia Neurodegenerative Disease Treatment Market Forecast
10.4 Europe Neurodegenerative Disease Treatment Forecast by Country (2025-2030)
10.4.1 Germany Neurodegenerative Disease Treatment Market Forecast
10.4.2 France Neurodegenerative Disease Treatment Market Forecast
10.4.3 UK Neurodegenerative Disease Treatment Market Forecast
10.4.4 Italy Neurodegenerative Disease Treatment Market Forecast
10.4.5 Russia Neurodegenerative Disease Treatment Market Forecast
10.5 Middle East & Africa Neurodegenerative Disease Treatment Forecast by Region (2025-2030)
10.5.1 Egypt Neurodegenerative Disease Treatment Market Forecast
10.5.2 South Africa Neurodegenerative Disease Treatment Market Forecast
10.5.3 Israel Neurodegenerative Disease Treatment Market Forecast
10.5.4 Turkey Neurodegenerative Disease Treatment Market Forecast
10.5.5 GCC Countries Neurodegenerative Disease Treatment Market Forecast
10.6 Global Neurodegenerative Disease Treatment Forecast by Type (2025-2030)
10.7 Global Neurodegenerative Disease Treatment Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Allergan plc
11.1.1 Allergan plc Company Information
11.1.2 Allergan plc Neurodegenerative Disease Treatment Product Offered
11.1.3 Allergan plc Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Allergan plc Main Business Overview
11.1.5 Allergan plc Latest Developments
11.2 Bayer AG
11.2.1 Bayer AG Company Information
11.2.2 Bayer AG Neurodegenerative Disease Treatment Product Offered
11.2.3 Bayer AG Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Bayer AG Main Business Overview
11.2.5 Bayer AG Latest Developments
11.3 F. Hoffmann La-Roche Ltd.
11.3.1 F. Hoffmann La-Roche Ltd. Company Information
11.3.2 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Product Offered
11.3.3 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 F. Hoffmann La-Roche Ltd. Main Business Overview
11.3.5 F. Hoffmann La-Roche Ltd. Latest Developments
11.4 GlaxoSmithKline plc
11.4.1 GlaxoSmithKline plc Company Information
11.4.2 GlaxoSmithKline plc Neurodegenerative Disease Treatment Product Offered
11.4.3 GlaxoSmithKline plc Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 GlaxoSmithKline plc Main Business Overview
11.4.5 GlaxoSmithKline plc Latest Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Neurodegenerative Disease Treatment Product Offered
11.5.3 Johnson & Johnson Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Johnson & Johnson Main Business Overview
11.5.5 Johnson & Johnson Latest Developments
11.6 Merck KGaA
11.6.1 Merck KGaA Company Information
11.6.2 Merck KGaA Neurodegenerative Disease Treatment Product Offered
11.6.3 Merck KGaA Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Merck KGaA Main Business Overview
11.6.5 Merck KGaA Latest Developments
11.7 Novartis AG
11.7.1 Novartis AG Company Information
11.7.2 Novartis AG Neurodegenerative Disease Treatment Product Offered
11.7.3 Novartis AG Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Novartis AG Main Business Overview
11.7.5 Novartis AG Latest Developments
11.8 Pfizer, Inc.
11.8.1 Pfizer, Inc. Company Information
11.8.2 Pfizer, Inc. Neurodegenerative Disease Treatment Product Offered
11.8.3 Pfizer, Inc. Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Pfizer, Inc. Main Business Overview
11.8.5 Pfizer, Inc. Latest Developments
11.9 Sanofi
11.9.1 Sanofi Company Information
11.9.2 Sanofi Neurodegenerative Disease Treatment Product Offered
11.9.3 Sanofi Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Sanofi Main Business Overview
11.9.5 Sanofi Latest Developments
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Information
11.10.2 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Product Offered
11.10.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
11.10.5 Teva Pharmaceutical Industries Ltd. Latest Developments
12 Research Findings and Conclusion